Have any questions about how to use the community? Check out the Help Discussion.

Good review article M1 receptor targeting

I came across this good review article from 2022 when I was looking for things to help my wife who is experiencing adverse effects from donepezil and rivastigmine.
It’s a good review article of the progress being made to develop drugs that have less adverse effects. Doesn’t look like anything is coming on the market anytime soon. But, if they can refine this class then there is potential for using them even in the severe stages to improve outcomes.

https://portlandpress.com/neuronalsignal/article/6/1/NS20210004/231109

Comments

  • allit
    allit Member Posts: 80
    10 Comments 5 Care Reactions 5 Insightfuls Reactions 5 Likes
    Member

    One thing that’s frustrating, Vanderbilt University developed a compound VU319 but then licensed it to Acadia Pharmaceuticals and it seems like since then there’s been no word on it.

  • allit
    allit Member Posts: 80
    10 Comments 5 Care Reactions 5 Insightfuls Reactions 5 Likes
    Member

    An article on Vanderbilt U and compound VU319. Mentions the Alzheimer’s Association Part the Cloud program

    https://www.vumc.org/ccm/sites/default/files/VU319%20ARTICLE%20FROM%20VU.pdf

Commonly Used Abbreviations


DH = Dear Husband
DW= Dear Wife, Darling Wife
LO = Loved One
ES = Early Stage
EO = Early Onset
FTD = Frontotemporal Dementia
VD = Vascular Dementia
MC = Memory Care
AL = Assisted Living
POA = Power of Attorney
Read more